bpc-157 dosing studies humans clinical trials dosage BPC-157 (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or BPC-157 Peptide: Benefits, Dosage &
Description
We use cookies to enhance your browsing experience and analyse our traffic
None of these topical formulations are FDA-approved, which means the agency has not evaluated their safety, efficacy, or quality prior to marketing
The net result is increased bone mass and density
Doing so, though, requires extensive time planning, shopping for, and preparing healthful meals each day
